Cargando…

RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis

BACKGROUND: Although the classic radiobiologic principles of radiotherapy are well understood, the unique effects of the large fractional does that characterize stereotactic radiotherapy (SRT), specifically in terms of antitumor immune cellular processes, vascular damage, tumor necrosis, and apoptos...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotecha, Rupesh, Tonse, Raees, Menendez, Miguel A Ramirez, Williams, Andre, Diaz, Zuanel, Tom, Martin C, Hall, Matthew D, Mehta, Minesh P, Siomin, Vitaly, Ahluwalia, Manmeet S, McDermott, Michael W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351174/
http://dx.doi.org/10.1093/noajnl/vdab071.081
_version_ 1783735914683432960
author Kotecha, Rupesh
Tonse, Raees
Menendez, Miguel A Ramirez
Williams, Andre
Diaz, Zuanel
Tom, Martin C
Hall, Matthew D
Mehta, Minesh P
Siomin, Vitaly
Ahluwalia, Manmeet S
McDermott, Michael W
author_facet Kotecha, Rupesh
Tonse, Raees
Menendez, Miguel A Ramirez
Williams, Andre
Diaz, Zuanel
Tom, Martin C
Hall, Matthew D
Mehta, Minesh P
Siomin, Vitaly
Ahluwalia, Manmeet S
McDermott, Michael W
author_sort Kotecha, Rupesh
collection PubMed
description BACKGROUND: Although the classic radiobiologic principles of radiotherapy are well understood, the unique effects of the large fractional does that characterize stereotactic radiotherapy (SRT), specifically in terms of antitumor immune cellular processes, vascular damage, tumor necrosis, and apoptosis on brain metastasis have yet to be adequately demonstrated. The objective of this study is to provide the first in-human evaluation of the biological effects of SRT in resected brain metastasis. METHODS: All paired primary tumors and metastases for patients who underwent dose-escalated preoperative SRT followed by resection were evaluated for tumor necrosis using hematoxylin-eosin staining. T cells (CD3+, CD4+, CD8+), natural killer cells (CD56+), vessel density (CD31+), and apoptotic factors (caspase-3) were determined by immunohistochemical analysis. RESULTS: Fifteen patients with brain metastases from solid tumors received a median preoperative SRT dose of 18 Gy (range: 15–18 Gy) in 1 fraction, with 2 patients receiving 27–30 Gy in 3–5 fractions, followed by resection within a median interval of 90 hours (Range: 17.1–260 hours). The rate of necrosis was found to be significantly higher in irradiated brain metastases than in non-irradiated primary tumor samples (mean paired difference: 30.47, SD: 29.28, p=0.001). A decrease in all immunomodulatory cell populations was found in irradiated metastasis: CD3 (mean paired difference -19.4, SD: 31.7, p=0.03), CD4 (-10.0, SD: 20, p=0.01), and CD8 (-17.4, SD: 22.1, p=0.008). While irradiated samples had numerically lower CD 31+, CD 56+, and caspase-3 scores, the difference was not statistically significant. Time interval from SRT to surgery had no effect on these parameters. CONCLUSIONS: There is complex interplay between tumor-associated cells and the unique radiobiological effects of SRT on tumor tissue. Although time interval from SRT to surgery was associated with increased tumor necrosis, differences in immunomodulatory factors may be multifactorial, including concurrent corticosteroids or the immunosuppressive effect of SRT.
format Online
Article
Text
id pubmed-8351174
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83511742021-08-09 RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis Kotecha, Rupesh Tonse, Raees Menendez, Miguel A Ramirez Williams, Andre Diaz, Zuanel Tom, Martin C Hall, Matthew D Mehta, Minesh P Siomin, Vitaly Ahluwalia, Manmeet S McDermott, Michael W Neurooncol Adv Supplement Abstracts BACKGROUND: Although the classic radiobiologic principles of radiotherapy are well understood, the unique effects of the large fractional does that characterize stereotactic radiotherapy (SRT), specifically in terms of antitumor immune cellular processes, vascular damage, tumor necrosis, and apoptosis on brain metastasis have yet to be adequately demonstrated. The objective of this study is to provide the first in-human evaluation of the biological effects of SRT in resected brain metastasis. METHODS: All paired primary tumors and metastases for patients who underwent dose-escalated preoperative SRT followed by resection were evaluated for tumor necrosis using hematoxylin-eosin staining. T cells (CD3+, CD4+, CD8+), natural killer cells (CD56+), vessel density (CD31+), and apoptotic factors (caspase-3) were determined by immunohistochemical analysis. RESULTS: Fifteen patients with brain metastases from solid tumors received a median preoperative SRT dose of 18 Gy (range: 15–18 Gy) in 1 fraction, with 2 patients receiving 27–30 Gy in 3–5 fractions, followed by resection within a median interval of 90 hours (Range: 17.1–260 hours). The rate of necrosis was found to be significantly higher in irradiated brain metastases than in non-irradiated primary tumor samples (mean paired difference: 30.47, SD: 29.28, p=0.001). A decrease in all immunomodulatory cell populations was found in irradiated metastasis: CD3 (mean paired difference -19.4, SD: 31.7, p=0.03), CD4 (-10.0, SD: 20, p=0.01), and CD8 (-17.4, SD: 22.1, p=0.008). While irradiated samples had numerically lower CD 31+, CD 56+, and caspase-3 scores, the difference was not statistically significant. Time interval from SRT to surgery had no effect on these parameters. CONCLUSIONS: There is complex interplay between tumor-associated cells and the unique radiobiological effects of SRT on tumor tissue. Although time interval from SRT to surgery was associated with increased tumor necrosis, differences in immunomodulatory factors may be multifactorial, including concurrent corticosteroids or the immunosuppressive effect of SRT. Oxford University Press 2021-08-09 /pmc/articles/PMC8351174/ http://dx.doi.org/10.1093/noajnl/vdab071.081 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Supplement Abstracts
Kotecha, Rupesh
Tonse, Raees
Menendez, Miguel A Ramirez
Williams, Andre
Diaz, Zuanel
Tom, Martin C
Hall, Matthew D
Mehta, Minesh P
Siomin, Vitaly
Ahluwalia, Manmeet S
McDermott, Michael W
RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis
title RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis
title_full RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis
title_fullStr RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis
title_full_unstemmed RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis
title_short RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis
title_sort radi-11. evaluating the tissue effects of dose-escalated pre-operative stereotactic radiotherapy for resectable brain metastasis
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351174/
http://dx.doi.org/10.1093/noajnl/vdab071.081
work_keys_str_mv AT kotecharupesh radi11evaluatingthetissueeffectsofdoseescalatedpreoperativestereotacticradiotherapyforresectablebrainmetastasis
AT tonseraees radi11evaluatingthetissueeffectsofdoseescalatedpreoperativestereotacticradiotherapyforresectablebrainmetastasis
AT menendezmiguelaramirez radi11evaluatingthetissueeffectsofdoseescalatedpreoperativestereotacticradiotherapyforresectablebrainmetastasis
AT williamsandre radi11evaluatingthetissueeffectsofdoseescalatedpreoperativestereotacticradiotherapyforresectablebrainmetastasis
AT diazzuanel radi11evaluatingthetissueeffectsofdoseescalatedpreoperativestereotacticradiotherapyforresectablebrainmetastasis
AT tommartinc radi11evaluatingthetissueeffectsofdoseescalatedpreoperativestereotacticradiotherapyforresectablebrainmetastasis
AT hallmatthewd radi11evaluatingthetissueeffectsofdoseescalatedpreoperativestereotacticradiotherapyforresectablebrainmetastasis
AT mehtamineshp radi11evaluatingthetissueeffectsofdoseescalatedpreoperativestereotacticradiotherapyforresectablebrainmetastasis
AT siominvitaly radi11evaluatingthetissueeffectsofdoseescalatedpreoperativestereotacticradiotherapyforresectablebrainmetastasis
AT ahluwaliamanmeets radi11evaluatingthetissueeffectsofdoseescalatedpreoperativestereotacticradiotherapyforresectablebrainmetastasis
AT mcdermottmichaelw radi11evaluatingthetissueeffectsofdoseescalatedpreoperativestereotacticradiotherapyforresectablebrainmetastasis